Anna Azvolinsky, PhD

Anna Azvolinsky, PhD

Freelance Science Writer and Cancer Network Contributor.

Follow Her on Twitter

Posts by Author

This slide show features some of the top highlights from the 2014 San Antonio Breast Cancer Symposium, including ovarian suppression in ER-positive breast tumors, tamoxifen for disease prevention, and immunotherapies for triple-negative breast cancer.

Long-term survival rates of patients after laparoscopic surgery for bladder cancer are similar to rates achieved with standard open surgery.

Accelerated partial breast irradiation was shown to be just as effective and safe as whole breast irradiation in early-stage breast cancer patients.

Tamoxifen given to women at high risk for breast cancer lowered the rate of estrogen receptor (ER)-positive breast cancer diagnosis in the IBIS-I trial.

This slide show features some of the top highlights on immunotherapies and other new agents in leukemia and lymphoma from the 2014 ASH Meeting.

Early-stage premenopausal ER-positive breast cancer patients who have received chemotherapy benefited from ovarian suppression with tamoxifen or exemestane.

The PD-1 inhibitor pembrolizumab showed activity and had an acceptable safety profile in heavily pretreated metastatic triple-negative breast cancer patients.

Results of a phase II study of a PI3K inhibitor in ER-positive breast cancer showed a trend toward improved progression-free survival.

Two studies presented at the 2014 ASH Meeting addressed whether an interim PET scan during and after an initial therapy can help guide treatment.

An oral inhibitor of isocitrate dehydrogenase 2 (IDH2), AG-221, has shown activity and potentially durable remissions in patients with acute myeloid leukemia.


By clicking Accept, you agree to become a member of the UBM Medica Community.